Researchers discover new HIV vaccine-related tool

February 23, 2012
SFU health scientist Ralph Pantophlet takes a close up look at a bacterium that he and his colleagues have discovered could help our immune system eliminate HIV.

(Medical Xpress) -- A new discovery involving two Simon Fraser University scientists could lead to a little known and benign bacterium becoming a vital new tool in the development of a vaccine against human immunodeficiency virus (HIV).

Ralph Pantophlet, a Faculty of Health Sciences assistant professor, and Kate Auyeung, his senior research assistant and lab manager at SFU, and scientists in Italy have made a breakthrough discovery about Rhizobium radiobacter.

The journal Chemistry & Biology has just published their research in its Feb. 24 issue.

The research team has discovered this harmless bacterium has on its surface sugar molecules that resemble those on the surface of .

This resemblance gives scientists a basis for developing a preventative vaccine, putting our immune system on guard against HIV.

HIV’s sugar molecules act as a cloaking device, preventing our immune system from detecting the virus until it has created several variant generations of itself.

By the time our immune system’s recognition has kicked in, weeks have elapsed, and HIV is several steps ahead of our body’s efforts to eliminate it.

Pantophlet and his colleagues believe the sugar molecules on Rhizobium radiobacter could be used to trigger our immune system to immediately recognize those on HIV, prompting more immediate awareness of the virus’ invasion.

“The irony of our discovery is not lost on us,” says Pantophlet. “We’ve found that a harmless species of a bacteria family that can cause tumours in the roots of legume plants could become a vital tool in the fight against one of the deadliest infectious diseases.”

Before Rhizobium radiobacter can become the basis of an anti-HIV vaccine, the scientists need to find a protein to which they can attach the bacterium’s sugar molecules. The protein is needed to properly trigger our ’s development of antibodies to the sugar molecules. Such antibodies would then recognize and target HIV’s sugar molecules because they resemble those on the .

This method of triggering antibodies’ development has led to the invention of successful sugar-based vaccines against diseases such as meningitis and childhood pneumonia.

“Two known proteins, tetanus toxoid and CRM197, a nontoxic recombinant variant of diphtheria toxin, are commonly used to develop these kinds of vaccines,” explains Pantophlet. “So a lot of the groundwork is there for us to be able to have a vaccine that could be tested in a lab first and then in clinical trials later on.”

Pantophlet and his colleagues are seeking grant funding from the Canadian Institutes for Health Research to continue their research.

If they get the grant, they hope to attach Rhizobium radiobacter’s to a protein and create vaccine candidates for testing within the next one to two years.

Explore further: External capsule protects gum disease-causing bacteria from immune response

More information: www.cell.com/chemistry-biology/home

Related Stories

Recognizing blood poisoning quickly

December 2, 2011

(Medical Xpress) -- Is the patient suffering from blood poisoning? To answer this question, the doctor draws a blood sample and sends it to a central laboratory for testing. This takes up valuable time, which could cost the ...

New tool enhances view of muscles

January 23, 2012

Simon Fraser University associate professor James Wakeling is adding to the arsenal of increasingly sophisticated medical imaging tools with a new signal-processing method for viewing muscle activation details that have never ...

Recommended for you

Targeting HIV in semen to shut down AIDS

August 18, 2015

There may be two new ways to fight AIDS—using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according ...

Vitamin D status related to immune response to HIV-1

June 15, 2015

Vitamin D plays an important part in the human immune response and deficiency can leave individuals less able to fight infections like HIV-1. Now an international team of researchers has found that high-dose vitamin D supplementation ...

HVTN 505 vaccine induced antibodies nonspecific for HIV

July 30, 2015

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection ...

Why HIV's cloak has a long tail

June 2, 2015

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.